Nutcracker Therapeutics
Emeryville
About Nutcracker Therapeutics
Nutcracker Therapeutics is a biotech company that develops and produces mRNA therapeutics on its proprietary, microfluidic, and biochip-based platform. The company specializes in a fully-integrated system for the production of mRNA-therapeutics at the push of a button that enables scalable on-demand experimental and manufacturing capacity, thereby enabling healthcare companies to produce complex multimodal therapeutics at point of care. Nutcracker Therapeutics combines the productivity of RNA biology with innovations inspired by semiconductor manufacturing techniques to develop a proprietary miniaturized platform that enables the rapid discovery, development, and manufacturing of mRNA therapies and vaccines. Its ACORN platform is a first-of-its-kind, computer-controlled RNA manufacturing system that starts with a nucleic acid sequence of interest and produces optimized nanoparticle-encapsulated RNA therapeutics on dedicated, single-use biochips. Igor Khandros and Benjamin Eldridge established the company in Emeryville, California in 2018.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 101 – 250
- Estimated revenue: $10K – $50K
- Total funding: $241.0M
- Funding stage: Late Stage Venture
- Last round: Series C (Mar 2022)
- Website: nutcrackerx.com
- Phone: (510) 473-8478
Industries & Categories
Biotechnology, Health Care, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/nutcracker-therapeutics-88912 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.